# Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)

> **NCT00336583** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 27 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00336583
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-12
- **Final completion:** 2008-01
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336583, "Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00336583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*